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The nematode Caenorhabditis elegans (C. elegans) is a popular invertebrate model
organism to study neurobiological disease states. This is due in part to the intricate
mapping of all neurons and synapses of the entire animal, the wide availability of
mutant strains, and the genetic and molecular tools that can be used to manipulate
the genome and gene expression. We have shown that, C. elegans develops a
conditioned preference for cues that had previously been paired with either cocaine or
methamphetamine exposure that is dependent on dopamine neurotransmission, similar
to findings using place conditioning with rats and mice. In the current study, we show
C. elegans also display a preference for, and self-exposure to, cocaine and nicotine.
This substance of abuse (SOA) preference response can be selectively blocked by
pretreatment with naltrexone and is consistent with the recent discovery of an opioid
receptor system in C. elegans. In addition, pre-exposure to the smoking cessation
treatment varenicline also inhibits self-exposure to nicotine. Exposure to concentrations
of treatments that inhibit SOA preference/self-exposure did not induce any significant
inhibition of locomotor activity or affect food or benzaldehyde chemotaxis. These data
provide predictive validity for the development of high-throughput C. elegans behavioral
medication screens. These screens could enable fast and accurate generation of data
to identify compounds that may be effective in treating human addiction. The successful
development and validation of such models would introduce powerful and novel tools
in the search for new pharmacological treatments for substance use disorders, and
provide a platform to study the mechanisms that underlie addictions.
Keywords: addiction research, cocaine, nicotine, invertebrate models, self-administration models, high-
throughput screening assays
INTRODUCTION
The impact of addiction on our society is profound and by all accounts is increasing. It
has been estimated that in the United States alone, addiction costs approach 200 billion
dollars (U.S. Department of Justice, 2010). Clearly, there is an acute need for a better
understanding of the neurobiological basis of addiction, as well as better and more effective
treatments to confront this growing epidemic. Animal models have provided much of our
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current understanding about the neuroscience of addiction
(Edwards and Koob, 2012). In particular, behavioral measures
used to model and study human addiction in animals (cf.,
Bell and Rahman, 2016) in conjunction with functional
neurobiological studies have provided us with an understanding
of basic reward circuitry (Koob and Volkow, 2010). Development
of pharmacotherapeutic medications is a promising avenue
to reduce the impact of substance use disorders; however,
few such treatments are currently available. Thus, additional
efforts are needed to identify molecular targets and novel
compounds for medications development. Work from our
group and others shows that the effects of substances of
abuse (SOAs) on neurobiology and behavior is phylogenetically
ancient, suggesting that invertebrates possess some of the
mechanisms that underlie addiction. Techniques historically used
to study behavioral aspects of SOAs in vertebrates such as
conditioned place preference (CPP) and SOA self-administration
(Tzschentke, 2007) have also been developed for invertebrates.
Elegant studies have shown SOA reward, withdrawal, and seeking
to opiates, cocaine, and amphetamines in crayfish (Huber et al.,
2011). In Drosophila melanogaster, ethanol (EtOH) conditioning
and self-administration paradigms have demonstrated that flies
develop conditioned preference responses to cues previously
paired with EtOH (Kaun et al., 2011). These data show that
even simple invertebrate animals can model what are widely
considered to be highly complex behaviors. However, this should
not be surprising as behavioral models using invertebrates have
played a key role in discovering the underlying molecular
mechanisms that provide the basis for learning and memory
(Kandel, 2001).
The nematode Caenorhabditis elegans has some major
advantages as a model organism to study neurobiology and
disease states (Hulme and Whitesides, 2011). C. elegans have
conserved neurobiological systems with established mapping
of all neurons and synapses in the entire animal. We have
shown that, C. elegans develops a conditioned preference for
cues that had previously been paired with either cocaine
or methamphetamine exposure that is similar to findings
using place conditioning with rats and mice (Musselman
et al., 2012; Katner et al., 2016). Moreover, conditioning
required functional dopamine neurotransmission (Musselman
et al., 2012). Additionally, with SOA pre-exposure, C. elegans
demonstrate tolerance (Grotewiel and Bettinger, 2015) and
sensitization (Lee et al., 2009) which are hallmarks of addiction
in humans. Together, these data indicate that C. elegans,
show behavioral responses to SOAs that are consistent with
those of higher level organisms. These data also indicate
that invertebrates, specifically C. elegans in this case, show
behavioral responses to addictive SOAs that are consistent
with those seen in more complex animals. Recent research
has established that C. elegans display depressed locomotion
and functional tolerance after contact with EtOH which is
mediated, in part, through the BK potassium channel which
may mediate behavioral sensitivity to EtOH in many species
including humans (Bettinger and Davies, 2014; Davis et al., 2014).
Importantly, the internal tissue concentration leading to the
effects of EtOH on locomotor activity in C. elegans is strikingly
similar to blood alcohol levels that produce intoxication in
humans (Alaimo et al., 2012). These data suggest that C. elegans
show a concentration-dependent attraction to EtOH that results
in EtOH self-exposure and significant tissue concentrations
of EtOH. We have discovered that this EtOH preference
response can be selectively blocked by pretreatment with the
pan-opioid receptor antagonist, a treatment for alcohol and
opiate use disorders, naltrexone, which is consistent with the
recent discovery of an opioid receptor system in C. elegans that
mediates responses to both appetitive stimuli (Cheong et al.,
2015) as well as nociception (Mills et al., 2016). In the current
work, we have expanded the use of such a treatment approach
on cocaine and nicotine preference and have examined the
effects of the nicotinic cholinergic partial agonist, and smoking
cessation treatment, varenicline, on nicotine preference (Gomez-
Coronado et al., 2018). The results suggest an opportunity to
establish and validate a high-throughput C. elegans behavioral
medications screening model for stimulant addiction. The
successful development and implementation of such models
would provide the field with powerful and novel tools in the
search for new pharmacological treatments for addictions, and
provide a platform to study the underlying mechanisms of these
agents.
Objective: To determine ifC. elegansmay be used to model the
behavioral aspects of stimulant self-administration and to screen
for putative addiction treatments.
MATERIALS AND METHODS
Drugs
Cocaine hydrochloride was received from the NIDA Drug
Supply Program, nicotine bitartrate was purchased from Sigma
Aldrich (St. Louis, MO, United States), and varenicline tartrate
was purchased from Biotang (Lexington, MA, United States).
Vehicle (0.97 mM HCl; salt equivalent of naltrexone HCl) and
naltrexone HCl (N-3136; FW 377.9; Sigma-Aldrich) were used to
pretreat animals prior to SOA preference testing. Benzaldehyde
(#418099; 99.5%; Sigma-Aldrich; FW 106.12) was used to
test for non-selective effects of naltrexone HCl. 2-nonanone
(99%; CAS 821-55-6; FW 142.24; Arcos Organics) was used
to show that animals could move away from the SOA target
zone.
Culture and Maintenance of Strains
The N2 Bristol wild-type (WT) strain was used in all assays.
All animals were maintained at 22◦C, and all general culturing
techniques have been described previously by Nass and Hamza
(2007). Worms were grown with E. coli strain NA22 as a food
source on maintenance plates, produced by filling 60-mm petri
dishes with 10-ml regular NGM agar [25 g bacto agar, 20 g bacto
peptone, 3 g NaCl, 1 L H20, 1 ml cholesterol (5 mg/ml 95%
ethanol), 1 ml 1 M CaCl2, 1 ml 1 M MgSO4, and 25 ml of
potassium phosphate buffer]. The potassium phosphate buffer
contained 5 g of K2HPO4 dibasic/anhydrous, 30 g of KH2PO4
monobasic, and 500 ml of H20, pH adjusted to 6.0 (Bianchi and
Driscoll, 2006).
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Adult worms were used for all experiments to control for any
effects of different sensitivities and responses to SOAs at varying
developmental stages. Worms were age synchronized by lysing
gravid adults with bleach and sodium hydroxide, allowing eggs
to be released into solution and hatched in M9 buffer (Bianchi
and Driscoll, 2006). After 18 h, hatched L1 larvae were washed
three times with water, plated, and maintained on NGM plates
with NA22 E. coli bacterial lawns until reaching adulthood.
Testing began approximately 72 h post-plating the L1 larvae,
when worms were adults.
6-well CostarTM cell culture plates were used to determine
SOA preference (Fisher cat. no. 07-200-80). Clear templates were
taped to the bottom each 6-well plate to create two 1.2 cm
diameter circular target zones within the 3.5 cm diameter of each
well. Test plates were produced by filling each well of the plates
with 3.8 ml of NaCl free agar (17 g bacto agar, 2.5 g bacto peptone,
1 L H20, 1 ml 1 M CaCl2, 1 ml 1 M MgSO4, and 25 ml of
potassium phosphate buffer). Cholesterol was not included in the
salt-free agar in order to obtain clearer images of worms during
testing. Although the lack of salts and cholesterol in the agar may
have long-term effects on worms, our previous work indicating
intact cue-conditioned learning (Musselman et al., 2012; Katner
et al., 2016) and the differential responses with the SOAs vs.
controls (food or benzaldehyde) show that the agar preparation
as used in this paradigm does not prevent normal chemotaxic
responses.
Treatment Agent Pretreatment Prior to
SOA Preference Testing
Worms were washed off maintenance plates with 15 ml of water
and transferred to 15 ml centrifuge tubes. Adults were allowed
to settle on the bottom of each tube for 5 min and then the
supernatant was removed. This was repeated two more times
with 10 ml of water to remove the majority of bacteria from the
worms. After the final removal of the supernatant, approximately
0.3–0.5 ml of worms were transferred to a 5 ml Eppendorf
tube and 3 ml of vehicle (0.97 mM HCl) or treatment agent
naltrexone HCl (10 mM; dose selected from Cheong et al. (2015),
or varenicline (1.0 or 9.0 mM) was added to each tube. The tubes
were placed on a nutator for 30 min prior to SOA preference
testing. Following vehicle or treatment agent, tubes were taken
off nutator and worms were allowed to settle to the bottom of
each tube for approximately 3 min and the supernatant was
removed to a point where worms were diluted to a ratio of
approximately one part worms to two parts vehicle or treatment
agent solution. Then, 4 ul aliquots, containing approximately 40–
80 worms, were pipetted into the center of each well of a 6-well
testing plate and excess liquid was removed from the worms
using a Kimwipe. Images of each well were taken 10 and/or
30 min after placing worms on test plates. It should be noted
that although 0.97 mM HCl controlled for the HCl ions in the
10 mM naltrexone, there was an osmotic difference between
the vehicle control and naltrexone exposure group and washing
with water may induce osmotic stress. Thus, control experiments
were conducted examining locomotor behavior (body bends)
and movement to control attractants (benzaldehyde and food)
to determine if such treatments affect either locomotor activity
or normal chemotaxis to other attractants. Moreover, we (and
others) have conducted washings with diH2O without effects
on locomotion or the ability to develop and display learned
responses to cues or preference responses to benzaldehyde (Law
et al., 2004; Musselman et al., 2012; Katner et al., 2016). As with
our previous work (Musselman et al., 2012; Katner et al., 2016)
we are interested in only counting worms in the target zones
because it provides comparable measures of elective responses
of animals moving into zones that contain either the SOA or
the vehicle. The vehicle zone controls for the application of a
substance of the same volume as the SOA target zone and effects
of that application to that space on the agar.
SOA Preference Testing Procedure
In general, 4 µl of vehicle and a SOA solution were applied to
the center of the 1.2 cm target zones of each well. These spotting
solutions were allowed to absorb into agar for 30 min prior
to testing. Cocaine preference was tested with 0, 50, 250, and
500 µM cocaine HCl concentrations. Nicotine preference was
tested with 0, 5, 50, and 100 mM nicotine concentrations. Vehicle
(water) and inhibitor agent solutions were prepared fresh, prior
to each day of testing. All concentrations of SOAs include the salt
and each experiment was conducted over 2 to 4 days.
Food and Benzaldehyde Preference
Food: 1 µl of water or food (NA22 bacterial solution) was
spotted to the two target zones of each well. Images were
taken at 30 min. Benzaldehyde: 2 µl of a 1%(v/v) benzaldehyde
solution dissolved in 25%(v/v) EtOH was spotted in one target
zone, while 25% EtOH was spotted in the opposite target zone,
30 min before testing. Images were taken at 30 min. The
amounts/concentrations of food and benzaldehyde were selected
to produce preference indices similar to those observed with
cocaine and nicotine in this paradigm.
Nonanone Aversion
Nonanone (an aversive compound) was spotted [2 µl of
10%(v/v)] to the outer edge of the SOA target zone of each well
(i.e., between the edge of the SOA target zone and the outer
edge of the well; see Figure 1) immediately after taking 30 min
images for SOA preference experiments in order to determine
if animals were capable of moving away from the SOA target
zones and were not rendered ataxic by the SOA test compounds
themselves. Therefore, images were taken immediately before
and 10 min after placing nonanone into each well. Pre- and post-
nonanone preference indexes (PIs) (as described below under
SOA preference testing) were calculated for each well in order
to compute the change in preference from the SOA target zone
in response to nonanone. In this way the effects of nonanone are
tested at the time and under the conditions in which the animals
are displaying the preference response.
Body Bend Assay
The body bend assay used here was adapted from Hart (2006).
After 30 min pretreatment with vehicle (0.97 mM HCl) or
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FIGURE 1 | (A) Caenorhabditis elegans screen for medications development. A popular method to assess how C. elegans respond behaviorally to a chemical is the
simple chemotaxis assay, which is a type of voluntary self-exposure paradigm. Worms were exposed to either vehicle (0.97 mM HCl) or test treatment agent
(naltrexone or varenicline) in a centrifuge tube for 30 min prior to the SOA preference testing to either cocaine or nicotine. Animals were then pipetted into the center
of each well of a 6-well agar test plate containing two target zones; one spotted with SOA and the other with vehicle. Images were taken 30 min after plating worms
to determine a SOA preference index for each well. The chemotaxic (preference/avoidance) index (CI) is calculated by dividing the number of worms in the target
zone containing the test substance by the total sum of worms counted in both zones. To indicate that the animals are not simply anesthetized by the SOA, after the
preference test has been established, a 2 µl drop of the aversive stimulus nonanone (red dot) is placed between the edge of the plate and the target zone and
another photograph is taken 5 min later to assess ability to determine if the presence in the target zone is the result of anesthesia. (B) A single well of a 6-well plate
spotted with 1% benzaldehyde (red target zone) and vehicle (green target zone): Images were taken immediately (left) and 30 min after (right) placing worms in the
center of the well. The benzaldehyde preference index for the well on the right at the 30 min time point was 83.3%.
naltrexone HCl (10 mM), 2 µl of worms diluted in a ratio
of one part worms to two parts vehicle or inhibitor agent
(as described above in the pretreatment section) were placed
on a microscope slide on the stage of a microscope (Bausch &
Lomb ASZ45L3 45X). After selecting a single worm to track, the
number of times the worm’s tip crossed this midline and extended
to about a 45–90 degree arc over a 20 s period was recorded.
Only instances where the midline was completely crossed were
counted.
Imaging and Worm Counting
Worms were imaged by taking pictures or video with a
smartphone positioned on top of a light box, which emitted light
indirectly and underneath each 6-well plate. Video time-course
files were compressed to time-lapse.mov files to illustrate worm
activity during preference tests (± pretreatment with naltrexone)
and the response to nonanone. Individual images were analyzed
using ImageJ software to count the number of worms in the
target zones of the test plates. Using ImageJ, the target zone
was cropped from each photo and the color threshold of the
image was adjusted. Specifically, threshold color was set to red,
color space was set to RGB, and color threshold was adjusted
so worms were highlighted in red. Particles were analyzed with
a pixel size of 80 to infinity. The number of worms counted
in each target zone was recorded and analyzed in Microsoft
Excel.
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FIGURE 2 | Pretreatment with 10 mM naltrexone decreased cocaine
preference in N2 C. elegans. A two-way ANOVA found a main effect of
cocaine concentration and a significant interaction between pretreatment and
cocaine concentration on cocaine preference. Significant factors were
decomposed using one-way ANOVAs followed by LSD post hoc tests.
∗Significant (p < 0.05) increase in cocaine preference in vehicle treated worms
compared to respective 0 mM cocaine (water). +Significant (p < 0.05)
decrease in preference for cocaine following 10 mM naltrexone pretreatment
compared to respective vehicle condition. The number of wells analyzed for
the vehicle treated groups were 24 (water), 18 (50 µM), 18 (250 µM), and 18
(500 µM), and for the naltrexone treated groups were 24 (water), 24 (50 µM),
24 (250 µM), and 24 (500 µM).
A chemotaxic PI for each SOA concentration was then
calculated by dividing the number of worms in the SOA target
zone by the total sum of worms counted in both the SOA and
vehicle zones converted to a percentage.
Statistical Analyses
All analyses were analyzed using one-, two-, or three-way
ANOVAs, followed by decomposition of factors and post hoc tests
as appropriate and previously conducted (Musselman et al., 2012;
Katner et al., 2016). Independent or paired t-tests were used to
compare two samples between or within groups, respectively.
Values in figures and tables are presented as mean± SEM.
RESULTS
Cocaine/Naltrexone
The effect of cocaine (0, 50, 250, or 500 µM) to induce preference
and the effect of pretreatment with 10 mM naltrexone to inhibit
the response are shown in Figure 2. Preference was found for
cocaine at the 250 and 500 µM concentrations, which was
eliminated by naltrexone pretreatment. A two-way ANOVA
found a main effect of cocaine concentration [F(3,174) = 2.7;
p< 0.05] and a significant interaction between pretreatment and
cocaine concentration [F(3,174) = 4.4, p < 0.006] on cocaine
preference. For vehicle pretreated worms, a one-way ANOVA
found a main effect of cocaine concentration on preference
[F(3,77) = 5.0; p < 0.004], and post hoc tests revealed significant
(p < 0.05) preference indices for 250 and 500 µM cocaine
compared to water. Post hoc tests also found significant (p< 0.05)
FIGURE 3 | Pretreatment with 10 mM naltrexone decreased nicotine
preference in N2 (wild-type) C. elegans. For naltrexone, a two-way ANOVA
decomposed and followed by LSD post hoc tests where appropriate found
main effects of concentration and treatment, and a significant interaction
between concentration and treatment on nicotine preference at 30 min.
∗Significant (p < 0.05) increase in nicotine preference in vehicle and
naltrexone treated worms compared to respective 0 mM nicotine. +Significant
(p < 0.05) decrease in preference for nicotine following 10 mM naltrexone
pretreatment compared to respective vehicle condition. The number of wells
analyzed for the vehicle treated groups were 36 (0 mM), 36 (5 mM), 36
(50 mM), and 24 (100 mM), and for the naltrexone treated groups were 36
(0 mM), 36 (5 mM), 36 (50 mM), and 24 (100 mM).
differences in cocaine preference between the 50 µM and 250 µM
cocaine concentrations, for vehicle treated worms. For naltrexone
pretreated worms, a one-way ANOVA did not find a main
effect of cocaine concentration on preference [F(3,95) = 1.3; ns].
One-way ANOVAs examining differences between vehicle and
naltrexone pretreatment for each cocaine concentration found no
main effect of pretreatment on water [F(1,47) = 2.0; ns] or 50 µM
cocaine [F(1,41) = 0.6; ns] preference. However, naltrexone
pretreatment decreased 250 µM [F(1,41) = 4.8, p < 0.04] and
500 µM [F(1,41) = 10.8, p< 0.003] cocaine preference compared
to vehicle pretreatment.
Nicotine/Naltrexone
The effect of nicotine (0, 5, 50, or 100 mM) to induce a preference
response and the effect of pretreatment with 10 mM naltrexone
to inhibit the response is shown in Figure 3 and Supplementary
Figure 1. For naltrexone, a two-way ANOVA found main effects
of concentration [F(3, 263) = 65.0; p < 0.001] and treatment
[F(1,263) = 25.3; p< 0.001], and a significant interaction between
concentration and treatment [F(3,263) = 5.4; p < 0.002] on
nicotine preference at 30 min. Overall, the findings indicate a
significant preference response at each nicotine concentration
that is significantly reduced by pretreatment with naltrexone
(Figure 3 and Supplementary Figure 1).
Nicotine/1 mM Varenicline
Varenicline pretreatment revealed robust effects at the 10 min
time point in some cases, thus preference data were analyzed
and presented for both the 10 and 30 min time points. The
effect of pretreatment with 1 mM varenicline to inhibit the
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FIGURE 4 | Pretreatment with 1 mM varenicline failed to modify nicotine
preference in N2 (wild-type) C. elegans. (A,B) Represent 10 and 30 min
nicotine preference, respectively. A two-way ANOVA decomposed and
followed by LSD post hoc where appropriate, found a main effect of nicotine
concentration on nicotine preference at 10 and 30 min. There was however,
no effect of 1 mM varenicline pretreatment on nicotine preference at either
time-point or nicotine concentration (p > 0.05). ∗Significant (p < 0.05)
increase in nicotine preference in vehicle and varenicline treated worms
compared to respective 0 mM nicotine. 1Significant (p < 0.05) increase in
preference for nicotine compared to respective 5 mM nicotine condition. The
number of wells analyzed for the vehicle treated groups were 12 (0 mM), 12
(5 mM), 12 (50 mM), and 9 (100 mM), and for the varenicline treated groups
were 12 (0 mM), 12 (5 mM), 12 (50 mM), and 11 (100 mM).
nicotine preference response is shown in Figure 4 at both the
10 min (A) and 30 min (B) time points. For 1 mM varenicline,
a two-way ANOVA found a main effect of nicotine concentration
[F(3,91) = 23.9; p < 0.001] on nicotine preference at 10 and
30 min. There was however no effect of 1 mM varenicline
pretreatment on nicotine preference at either time-point or
nicotine concentration (p> 0.05).
Nicotine/9 mM Varenicline
The effect of pretreatment with 9 mM varenicline to inhibit
the nicotine preference response is shown in Figure 5 at
both the 10 min (A) and 30 min (B) time points. A three-
way ANOVA found main effects of time (10 and 30 min)
[F(1,84) = 20.4; p < 0.001], concentration [F(3,84) = 24.5;
p < 0.001], treatment [F(1,84) = 65.0; p < 0.001], a significant
interaction between concentration and treatment [F(3,84) = 5.2;
p < 0.003], and a significant interaction between time and
treatment [F(1,84) = 16.3; p < 0.001] on nicotine preference.
FIGURE 5 | Pretreatment with 9 mM varenicline decreased nicotine
preference in N2 (wild-type) C. elegans. (A,B) represent 10 and 30 min
nicotine preference, respectively. A three-way ANOVA decomposed and
followed by LSD post hoc tests where appropriate, found main effects of time
(10 and 30 min), concentration, treatment, a significant interaction between
concentration and treatment, and a significant interaction between time and
treatment on nicotine preference. ∗Significant (p < 0.05) increase in nicotine
preference in vehicle and varenicline treated worms compared to respective
0 mM nicotine. +Significant (p < 0.05) decrease in preference for nicotine
following varenicline pretreatment compared to respective vehicle condition.
The number of wells analyzed for the vehicle treated groups were 12 (0 mM),
12 (5 mM), 10 (50 mM), and 11 (100 mM), and for the varenicline treated
groups were 11 (0 mM), 12 (5 mM), 12 (50 mM), and 12 (100 mM).
Overall, pretreatment with 9.0 mM varenicline significantly
reduced the preference response to nicotine at both time points.
Benzaldehyde Preference
The effect of pretreatment with 10 mM naltrexone to modify
benzaldehyde preference was conducted in order to examine the
effect naltrexone on the preference response to a known volatile
attractant. An independent t-test found that naltrexone (10 mM)
pretreatment had no significant effect [t = 0.97; ns] on 1% (v/v)
benzaldehyde preference (PI = 84.4± 4.0%; n = 12) compared to
vehicle (0.97 mM HCl) pretreatment (PI = 84.9± 8.6%; n = 12).
Nonanone Aversion
In order to determine if animals were anesthetized after moving
into target zones containing either cocaine or nicotine, the
aversive compound nonanone was applied between the target
zone and the edge of the plate after the animals had established a
preference response. Independent t-tests found significant effects
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FIGURE 6 | Caenorhabditis elegans retained the ability to move away from the aversive compound, nonanone. Nonanone application significantly reduced the
preference value for nicotine (5, 50, and 100 mM) or cocaine (250 and 500 µM). Independent t-tests found significant effects of nonanone on 250 and 500 µM
cocaine preference (p < 0.001). Paired t-tests found significant effects of nonanone on 5, 50 and 100 mM nicotine preference (p < 0.05). ∗Significant (p < 0.05)
decrease in SOA preference post nonanone compared to respective pre-nonanone preference for a given SOA concentration. For nicotine, the number of wells
analyzed for the pre-nonanone condition were 36 (5 mM), 36 (50 mM), and 24 (100 mM), and for the post-nonanone condition were 36 (5 mM), 36 (50 mM), and 24
(100 mM). For cocaine, the number of wells analyzed for the pre-nonanone condition were 12 (250 µM) and 12 (500 µM), and for the post-nonanone condition were
6 (250 µM) and 6 (500 µM).
of nonanone on 250 and 500 µM cocaine preference (p < 0.001;
Figure 6). Paired t-tests found significant effects of nonanone on
5, 50, and 100 mM nicotine preference (p< 0.05; Figure 6).
Video of SOA Preference, the Response
to Nonanone, and the Effect of
Naltrexone Pretreatment
To better illustrate the development of drug preference and
the aversive response to nonanone in this paradigm, videos of
a preference test with 100 mM nicotine and the subsequent
response to nonanone were recorded and compressed into
time-lapsed format and are presented in Supplementary
Video 1. A similar time-lapsed video illustrating the effects of
pretreatment with 10 mM naltrexone on the preference test with
100 mM nicotine is presented in Supplementary Video 2.
Food Preference
For vehicle and naltrexone pretreatment, both conditions showed
a normal chemotaxis to food and food preference was 86.1 ± 2.8
and 80.3 ± 5.7%, respectively (Table 1). An independent
t-test found no significant effect of pretreatment (vehicle vs.
naltrexone) on food preference [t = 2.1; ns]. In addition,
9 mM varenicline pretreatment did not significantly affect food
preference (Table 1). An independent t-test found no effect of
varenicline on food preference [t = 2.2; ns].
Locomotor Activity
Naltrexone: We found that exposure to 10 mM naltrexone for
30 min prior to testing had no significant effect on locomotor
activity compared to vehicle exposure [F(1,11) = 0.02; ns].
Specifically, the number of body bends in 20 s for vehicle and
TABLE 1 | Food preference in N2 C. elegans following vehicle and inhibitor agent
treatment.
Agent Vehicle Inhibitor Treated
Naltrexone (10 mM) 86.1 ± 2.8% 80.3 ± 5.7%
Varenicline (9 mM) 84.0 ± 3.6% 80.7 ± 5.0%
t-tests found that inhibitor agent treatments had no effect on food preference. The
number of wells analyzed for naltrexone were 12 for vehicle and 12 for naltrexone.
The number of wells analyzed for varenicline were 12 for vehicle and 12 for
varenicline.
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naltrexone treatments were 54 ± 7 (n = 6) and 53 ± 3 (n = 6),
respectively.
Varenicline: Mean (±SEM) body bends/20 s for vehicle treated
worms were 46.3± 3.6 (n = 9), while body bends were 47.0± 3.6
(n = 8) for varenicline (9 mM) treated worms. Independent t-tests
found no significant difference in body bends after varenicline
treatment.
DISCUSSION
The present studies found a concentration-dependent attraction
by C. elegans to the SOAs cocaine (Figure 2) and nicotine
(Figures 3–5 and Supplementary Video 1). Naltrexone
pretreatment selectively reduced preference for both cocaine
(Figure 2) and nicotine (Figure 3, Supplementary Figure 1 and
Supplementary Video 2) in this paradigm, but had no effect on
preference for food or benzaldehyde preference. Moreover, the
SOA preference response was not likely due to an anesthetic or
paralytic effect, since worms were able to move away from the
SOA target zones following the application the chemorepellent,
nonanone (Figure 6 and Supplementary Video 1), and continue
to move in the SOA target zone after entering (Supplementary
Video 1). Pretreatment with varenicline, a treatment agent
approved for smoking cessation in humans, also was found to
reduce the nicotine preference response at concentrations that
did not affect locomotor activity or food preference. These data
are consistent with observations in vertebrate animal models
showing efficacy and selectivity of the SOAs and begins to
provide face and predictive validity for the model in medications
screening applications. Importantly, the 6-well plates enable
a high-throughput system for behavioral screening, and are
able to reduce the number of C. elegans needed to conduct
preference testing. This also limits the time required for imaging,
and ultimately enhances throughput. Combined, these findings
suggest that procedures using C. elegans may be developed to
screen medications for the treatment of substance use disorders.
In addition, the development of this technology will allow for the
future investigation of the molecular mechanisms that underlie
the efficacious effects of novel agents using the fully tractable
C. elegans model.
A popular method to assess how C. elegans respond
behaviorally to a chemical or substance is the simple chemotaxis
assay (Bargmann and Horvitz, 1991; Bargmann, 2006) which, in
fact, is a type of voluntary self-exposure paradigm. In the current
studies, we employed a modified version of this assay, in which a
6-well agar test plate was prepared with a SOA placed in a defined
target region on one side of each well and the vehicle, usually
water, placed in a target zone on the other side of each well. The
current experiments build on our previous work showing that
C. elegans show conditioned attraction to cues (either a salt or
food cue) previously paired with cocaine or methamphetamine
which utilized a procedure analogous to Pavlovian conditioning
models of reward in rodents (Musselman et al., 2012; Katner
et al., 2016). The current work examines preference responses to
two of the most widely abused stimulants, cocaine and nicotine
(Lee et al., 2009; Ward et al., 2009; Musselman et al., 2012;
Sellings et al., 2013). Few studies have examined the reinforcing
properties of stimulants in C. elegans; however, Sellings et al.
(2013), demonstrated that C. elegans show a concentration
dependent attraction to nicotine applied to agar test plates which
were confirmed in the current findings with nicotine. It should
be noted that the concentrations of treatment agents needed
to produce effects in C. elegans in these studies and in the
current study are often high due to the waxy cuticle that encases
the animal and functions as a barrier to entry (Epstein, 1995;
Davies et al., 2003; Cheong et al., 2015). In the current work,
animals counted in the target zone containing the stimulant
(either cocaine or nicotine) are in contact with the SOA and
thus demonstrating self-exposure to the SOA. This is also a true
choice behavior, since the current study found that the addition
of the aversive compound nonanone near the SOA target zone,
after the preference response has been established, caused the
animals to immediately move away from the SOA target zone,
inducing a measurable aversive response. These findings confirm
that the SOAs tested here are not simply functioning as a simple
locomotor anesthetic or paralytic agent in this procedure.
Consistencies in responses to SOAs across phyla led to the
hypothesis that C. elegans may be a viable model system to
screen potential candidate treatment for substance use disorders.
Recently, C. elegans were found to have functional opioid-
like receptors (Cheong et al., 2015). Thus, to determine the
predictive validity of the model, we tested the effectiveness
of naltrexone to decrease preference responses, as it is one
of the very few compounds shown consistently to reduce
alcohol and other SOAs intake and seeking behavior in animal
models as well as humans (Heilig and Egli, 2006). Using
vertebrate models, naltrexone has been demonstrated to reduce
cocaine intake (Mello et al., 1990; Corrigall and Coen, 1991;
Ramsey and van Ree, 1991) and seeking (Giuliano et al.,
2013); opioid intake in animal models and humans (Negus
and Banks, 2013), and has recently been shown to decrease
cannabis self-administration and subjective effects in chronic
cannabis users (Haney et al., 2015). Naltrexone has shown mixed
effects on nicotine use in humans (Aboujaoude and Salame,
2016; Barboza et al., 2016; Kirshenbaum et al., 2016). Rodent
studies indicate that naltrexone can reduce nicotine-induced
locomotor sensitization (Goutier et al., 2016) self-administration
at 2.0 mg/kg (Guy et al., 2014) but not 1.0 mg/kg or below
(Le et al., 2014). Also, treatment with naloxanazine (a selective
mu1 opioid receptor antagonist) significantly reduced nicotine
self-administration in rats (Liu and Jernigan, 2011). However,
some work suggests that naltrexone may have more consistent
effects to reduce conditioned responses to nicotine (Liu et al.,
2009). Other opioid receptors may also be efficacious targets,
with the kappa-opioid receptor antagonist nor-binaltorphimine
reducing nicotine seeking behavior (Grella et al., 2014). Together,
these studies support a role for opioid systems in stimulant
reinforcement and use and are consistent with findings in
the current screen with C. elegans. However, much additional
investigation is needed to identify how the opioid system may
be involved in nicotine self-administration and how agents that
target these systems may reduce tobacco or cocaine use in
humans.
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Based on the data presented here, we anticipate that potential
compounds that have efficacy in reducing SOA intake and/or
seeking in vertebrate models and humans will also inhibit the
SOA preference response in C. elegans. Naltrexone pre-exposure
clearly reduced SOA preference (Figures 2–3) at concentrations
that do not inhibit food consumption (Table 1), benzaldehyde
chemotaxis, or locomotor activity (body-bend data). These data
are consistent with rodent data showing that naltrexone can
inhibit intake of SOAs at doses that do not affect sucrose
intake or body weight (Henderson-Redmond and Czachowski,
2014). In most instances, little or no prior work has been
published to determine if treatment agents used to treat stimulant
addictions have effects on models of addictive responses to
stimulants in C. elegans. However, varenicline pre-exposure has
been shown to reduce chemotaxis to nicotine in C. elegans
(Sellings et al., 2013). Our data are consistent with these data
and show selectivity and predictive validity of varenicline in this
screening model. Varenicline is a partial agonist at the α4β2
receptor in vertebrates and is an approved treatment for nicotine
addiction (Crooks et al., 2014). Although it is still unclear how
varenicline reduces nicotine preference in C. elegans, attraction
to nicotine may be mediated through the acr-5 and acr-15
nicotinic acetylcholine receptors (Sellings et al., 2013). Other
possible mechanisms such as changes in drug metabolism or
subtle changes in sensory systems have yet to be investigated.
Interestingly, the effect of varenicline to inhibit nicotine self-
exposure in this paradigm is evident at the 10-min time point
and, although still evident at 30 min, appears to degrade over time
(Figure 5). This could be a reflection of the apparent strength
of the nicotine preference response, or possibly rapid clearance
of varenicline. In support of this idea is the apparent greater
strength of the preference response, and resistance to nonanone
for nicotine compared with cocaine at the concentrations used
in this study (Figure 6). Although it is somewhat difficult to
make direct comparisons between the cocaine and nicotine data
due to the differences in systems and mechanisms, and also
in concentrations used to produce the respective preference
responses, there are clear differences in the response to nonanone.
One possible explanation is that animals are being paralyzed by
the SOAs at these concentrations. This cannot be completely
ruled out as previous work has indicated that nicotine uniformly
mixed in agar to concentrations from 1 to 10 mM can induce
paralysis (Sobkowiak et al., 2011). However, other evidence
argues against the idea that the worms are paralyzed. First,
although the concentrations of cocaine and nicotine contacting
the worms in the target zones are not known, only 4 µl of SOA
was absorbed into a target zone in a well containing 3.8 mls of
agar, indicating the concentrations contacting the worms was
likely much lower than the concentrations added to the target
zones. Secondly, both groups of animals show a significant effect
of nonanone to move the animals from the SOA target zone
(although the magnitude of the effect was less for nicotine),
indicating that they are not paralyzed. This hypothesis is further
supported by examination of time-lapse videos (Supplementary
Video 1) which clearly show animals continuing to move in
the nicotine target zone after entering during a preference
test on a plate spotted with 100 mM nicotine, and a clear
movement out of the zone after the addition of nonanone. One
possible explanation for the greater effect of nonanone to displace
cocaine exposing animals compared to nicotine is the somewhat
stronger preference response observed with nicotine vs. cocaine
in these assays (Figure 6). The increased preference response for
nicotine over cocaine suggests a greater reinforcing property of
the SOA as tested and as such would confer greater aversion
resistance. Future experiments will provide additional evaluation
and characterization of varenicline and other compounds to
inhibit the SOA preference response. Such work is needed to
further demonstrate predictive validity and provide a strong
case for the model’s utility as a screening tool to help identify
compounds that have potential as treatments for SOA and alcohol
use disorders.
Behavioral studies of addictive SOAs in C. elegans to date
have mostly focused on EtOH (Grotewiel and Bettinger, 2015;
Engleman et al., 2016). Additional studies with other SOAs
are needed to better characterize the mechanisms that underlie
addictive properties of SOAs across the many classes of SOAs and
how they may be consistent or divergent across species. In the few
studies conducted thus far, several molecular targets have been
identified in various behavioral paradigms across SOA classes
using C. elegans (Engleman et al., 2016). Thus far, it appears that
genes involved in monoamine neurotransmission mediate at least
some behaviors induced by each SOA (Bettinger and McIntire,
2004; Lee et al., 2009; Ward et al., 2009; Musselman et al., 2012;
Sellings et al., 2013; Topper et al., 2014; Matsuura and Urushihata,
2015). In particular, mutation of the gene coding for tyrosine
hydroxylase (cat-2) reduced or inhibited SOA-induced behaviors
for each SOA of abuse (Bettinger and McIntire, 2004; Musselman
et al., 2012; Matsuura and Urushihata, 2015). It is widely thought
that the dopamine neurotransmitter system plays an important
role in drug abuse (Koob, 1992; Koob and Volkow, 2010)
and all of the SOAs discussed here have effects on dopamine
neurotransmission. Similarly, in agreement with the current
data, previous work has shown that manipulations that inhibit
cholinergic neurotransmission in C. elegans will also affect the
behavioral response to nicotine (Feng et al., 2006; Sellings et al.,
2013) and the effects of varenicline may be due in part to its effect
in modulating dopamine neurotransmission (Crooks et al., 2014).
Overall, the known mechanisms of action of SOAs in vertebrate
animals thus far show parallel findings in C. elegans and other
invertebrates. The effects of SOAs in C. elegans appear likely to be
mediated by neurobiological systems associated with many genes
and proteins that are known to mediate and/or support neuronal
function in higher level organisms (for review see Engleman et al.,
2016). However, since most of the work in C. elegans thus far
has focused heavily on EtOH, additional studies are needed to
determine if these mechanisms are also involved in other SOAs
using the C. elegans as a model system. Since the contributions
of the olfactory/chemosensory systems and specific mechanisms
of attraction and self-exposure will likely changes across various
classes of drugs of abuse, such differences may provide further
insight into the addictive properties of individual drugs and will
be a key focus of future studies.
Although C. elegans phenotypes are surprisingly highly
conserved functionally, with few clear differences in
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neurobiology, pharmacology, and molecular systems between
vertebrates and C. elegans. Moreover, C. elegans simple nervous
system lacks the complex neurocircuitry of mammals that have
been found to be involved in addiction (Koob and Volkow,
2010). However, the similarities in responses to SOAs between
C. elegans and mammals suggests that the behavioral responses
to SOAs may rely more on functional similarities in terms of how
SOAs affect systems that mediate survival (food) of the species
rather than complexities in the neuroanatomy. Interestingly,
differences in receptor systems and molecular pharmacology
in C. elegans could also provide an advantage of this model
providing a unique perspective concerning how some classes
of putative treatments affect SOAs. As an example, topiramate
is under investigation as a possible treatment for EtOH use
disorders (Johnson, 2004). Topiramate has a rich pharmacology
and there are several possible molecular mechanisms for reducing
EtOH drinking behavior. One suggested mechanism is activity
at voltage-sensitive sodium channels (Johnson, 2004), which are
not present in C. elegans (Bargmann, 1998). If topiramate were to
be found ineffective in C. elegans assays of EtOH self-exposure,
the data would support the contention that sodium channels may
have a role in reducing SOA intake/seeking in vertebrates. Thus,
cross-species findings could be assessed with respect to molecular
homology of the mechanisms thought to be mediating SOA
taking and/or preference. This could be conducted across SOA
classes to identify the effects of divergent molecular structure or
function on the results. Overall, such investigations may help to
characterize the molecular and pharmacological foundations of
the effects of these compounds, whether or not the findings are
consistent with the anticipated results.
Further development of the model employed here is
anticipated to provide the field with a new and powerful tool
to discover novel targets and treatments for addiction. This
work will combine the advances in our knowledge of human
addiction and insight gained through the use of vertebrate
behavioral models, and apply them to invertebrate models with
tremendous advantages and potential for discovery on a number
of levels: (a) the current work contributes to the establishment
of a new behavioral model in C. elegans for screening candidate
compounds to treat stimulant addictions; (b) in addition, the
ability to manipulate genes and gene expression quickly, and
the availability of many mutant strains in this well studied and
simple organism, greatly enhances the capability to discover
specific genes and proteins involved in SOA preference behavior
in this model; (c) the low cost and potential to fully automate
the assays allows for a dramatic increase in the number of
experiments that can be conducted for a fraction of the cost
and time needed with other animal models. Thus, this model
might be used in conjunction with gene editing techniques like
CRISPR where C. elegans receptors can be replaced with their
human orthologs to create transgenic C. elegans that might show
human-like pharmacology. Such an application could improve
the translational utility of the model and possibly enhance
predictive validity.
Once a high-throughput system is fully established, one
could conceivably screen entire potential treatment agent
libraries using tiny amounts of expensive compounds relative to
other animal models. Future collaborative projects will employ
transgenic approaches to express human genes in this model
to enhance the predictive validity of the model. Finally, the
data will be bi-directionally informative with other animal
models of medications development for substance use disorders
and compounds in clinical trials, such that the diversity in
pharmacology and molecular systems between different species
will help to better identify the mechanisms of action of putative
and/or validated treatment compounds.
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